Autolus Therapeutics (AUTL) Competitors $2.37 +0.02 (+0.85%) Closing price 03:53 PM EasternExtended Trading$2.37 0.00 (0.00%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AUTL vs. BHC, GMTX, APLS, ARWR, TWST, VCEL, KNSA, NAMS, DNLI, and RXRXShould you be buying Autolus Therapeutics stock or one of its competitors? The main competitors of Autolus Therapeutics include Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), Twist Bioscience (TWST), Vericel (VCEL), Kiniksa Pharmaceuticals International (KNSA), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "pharmaceutical products" industry. Autolus Therapeutics vs. Its Competitors Bausch Health Cos Gemini Therapeutics Apellis Pharmaceuticals Arrowhead Pharmaceuticals Twist Bioscience Vericel Kiniksa Pharmaceuticals International NewAmsterdam Pharma Denali Therapeutics Recursion Pharmaceuticals Bausch Health Cos (NYSE:BHC) and Autolus Therapeutics (NASDAQ:AUTL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment. Which has preferable valuation & earnings, BHC or AUTL? Bausch Health Cos has higher revenue and earnings than Autolus Therapeutics. Bausch Health Cos is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBausch Health Cos$9.63B0.27-$46M-$0.11-63.17Autolus Therapeutics$10.12M62.33-$220.66M-$0.88-2.69 Do institutionals and insiders hold more shares of BHC or AUTL? 78.7% of Bausch Health Cos shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 8.1% of Bausch Health Cos shares are owned by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media refer more to BHC or AUTL? In the previous week, Bausch Health Cos had 4 more articles in the media than Autolus Therapeutics. MarketBeat recorded 8 mentions for Bausch Health Cos and 4 mentions for Autolus Therapeutics. Bausch Health Cos' average media sentiment score of 0.61 beat Autolus Therapeutics' score of 0.28 indicating that Bausch Health Cos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer BHC or AUTL? Bausch Health Cos currently has a consensus target price of $7.42, suggesting a potential upside of 6.73%. Autolus Therapeutics has a consensus target price of $9.32, suggesting a potential upside of 293.25%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Bausch Health Cos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch Health Cos 1 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.86Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BHC or AUTL more profitable? Autolus Therapeutics has a net margin of 0.00% compared to Bausch Health Cos' net margin of -0.41%. Autolus Therapeutics' return on equity of -52.82% beat Bausch Health Cos' return on equity.Company Net Margins Return on Equity Return on Assets Bausch Health Cos-0.41% -540.45% 5.26% Autolus Therapeutics N/A -52.82%-29.67% Which has more risk & volatility, BHC or AUTL? Bausch Health Cos has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. SummaryAutolus Therapeutics beats Bausch Health Cos on 9 of the 16 factors compared between the two stocks. Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AUTL vs. The Competition Export to ExcelMetricAutolus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$630.75M$2.89B$5.49B$9.01BDividend YieldN/A2.64%5.39%4.09%P/E Ratio-2.6921.5627.4320.06Price / Sales62.33281.29398.25108.31Price / CashN/A41.4736.1356.90Price / Book1.477.518.085.67Net Income-$220.66M-$55.05M$3.16B$248.47M7 Day Performance2.60%3.16%2.12%2.90%1 Month Performance14.49%5.92%4.43%5.75%1 Year Performance-32.09%5.82%35.62%21.36% Autolus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AUTLAutolus Therapeutics2.7003 of 5 stars$2.37+0.9%$9.32+293.2%-30.5%$630.75M$10.12M-2.69330Positive NewsBHCBausch Health Cos3.2721 of 5 stars$6.11-1.1%$7.42+21.4%+0.0%$2.26B$9.73B-55.5520,700GMTXGemini TherapeuticsN/A$51.61+3.0%N/A+10.0%$2.24BN/A-51.6130High Trading VolumeAPLSApellis Pharmaceuticals4.5231 of 5 stars$17.62-0.4%$40.05+127.3%-49.1%$2.21B$775.84M-9.84770Trending NewsAnalyst ForecastAnalyst RevisionARWRArrowhead Pharmaceuticals3.9262 of 5 stars$15.51+1.2%$43.71+181.8%-33.0%$2.14B$3.55M-11.08400TWSTTwist Bioscience4.4042 of 5 stars$35.33+2.0%$50.40+42.7%-20.4%$2.12B$347.68M-10.87990News CoveragePositive NewsVCELVericel2.8916 of 5 stars$41.80-0.5%$61.14+46.3%-8.0%$2.10B$237.22M1,393.80300KNSAKiniksa Pharmaceuticals International3.6962 of 5 stars$28.72+1.0%$38.80+35.1%+48.7%$2.10B$423.24M-114.88220NAMSNewAmsterdam Pharma3.0459 of 5 stars$18.21+1.4%$42.89+135.5%-6.6%$2.04B$45.56M-9.694DNLIDenali Therapeutics4.5383 of 5 stars$13.62-1.9%$33.71+147.5%-31.5%$1.98B$330.53M-5.10430RXRXRecursion Pharmaceuticals1.9452 of 5 stars$4.83-4.0%$7.00+44.9%-27.2%$1.96B$58.84M-2.73400Analyst Forecast Related Companies and Tools Related Companies Bausch Health Cos Competitors Gemini Therapeutics Competitors Apellis Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Twist Bioscience Competitors Vericel Competitors Kiniksa Pharmaceuticals International Competitors NewAmsterdam Pharma Competitors Denali Therapeutics Competitors Recursion Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AUTL) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
